GENETIC FACTORS ASSOCIATED WITH RESPONSE TO INTRAVITREAL RANIBIZUMAB IN KOREAN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION
The DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
Abstract
In Brief Purpose: To investigate the association between genetic risk variants for age-related macular degeneration (AMD) and response to intravitreal ranibizumab in Korean patients with neovascular AMD. Methods: This prospective study included 273 treatment-naive patients (273 eyes) who underwent 5 monthly injections (Months 0, 1, 2, 3, and 4) of intravitreal ranibizumab for neovascular AMD. Patients were genotyped for 23 single-nucleotide polymorphisms within 12 AMD-relevant genes. For each polymorphism, genotypic association with good response at Month 5, predetermined as visual improvement of ≥8 Early Treatment Diabetic Retinopathy Study letters from baseline, was investigated with logistic regression analysis adjusted for age, gender, smoking, baseline Early Treatment Diabetic Retinopathy Study letter, central retinal thickness, lesion area, and type of choroidal neovascularization. Results: At Month 5, visual acuity improved by 9.1 ± 17.6 letters from baseline, and 136 patients (49.8%) were classified as good responders. In logistic regression, no tested polymorphism showed statistically significant association with favorable visual outcome at Month 5. When unadjusted for multiple tests, AA genotype for VEGF rs699947 had an increased chance of good response compared with other genotypes (odds ratio, 3.61; 95% confidence interval, 1.42–9.18; P = 0.0071). Conclusion: In this Korean neovascular AMD cohort, there was no statistically significant effect of genotype on early visual outcome after ranibizumab treatment. A prospective cohort study including 273 treatment-naive Korean patients with neovascular age-related macular degeneration showed no statistically significant association between 23 age-related macular degeneration–relevant genetic risk variants and treatment outcome after 5 monthly injections of intravitreal ranibizumab.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hageman, G. S., Anderson, D. H., Johnson, L. V., Hancox, L. S., Taiber, A. J., Hardisty, L. I., Hageman, J. L., Stockman, H. A., Borchardt, J. D., Gehrs, K. M., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0501536102 · Cited by 1,961
Bird, A. C., Bressler, N. M., Bressler, S. B., Chisholm, I. H., Coscas, G., Davis, M. D., de Jong, P. T. V. M., Klaver, C. C. W., Klein, B. E. K., Klein, R., et al. (1995) · Survey of Ophthalmology · doi:10.1016/s0039-6257(05)80092-x · Cited by 1,926
Chen, W., Stambolian, D., Edwards, A. O., Branham, K. E., Othman, M., Jakobsdottir, J., Tosakulwong, N., Pericak-Vance, M. A., Campochiaro, P. A., Klein, M. L., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0912702107 · Cited by 506
Yu, Y., Bhangale, T. R., Fagerness, J., Ripke, S., Thorleifsson, G., Tan, P. L., Souied, E. H., Richardson, A. J., Merriam, J. E., Buitendijk, G. H. S., et al. (2011) · Human Molecular Genetics · doi:10.1093/hmg/ddr270 · Cited by 254
Brantley, M. A., Fang, A. M., King, J. M., Tewari, A., Kymes, S. M., & Shiels, A. (2007) · Ophthalmology · doi:10.1016/j.ophtha.2007.09.008 · Cited by 201
Klein, M. L., Francis, P. J., Rosner, B., Reynolds, R., Hamon, S. C., Schultz, D. W., Ott, J., & Seddon, J. M. (2008) · Ophthalmology · doi:10.1016/j.ophtha.2008.01.036 · Cited by 172
Lee, A. Y., Raya, A. K., Kymes, S. M., Shiels, A., & Brantley, M. A. (2009) · British Journal of Ophthalmology · doi:10.1136/bjo.2008.150995 · Cited by 134
Genetic association with response to intravitreal ranibizumab in patients with neovascular AMD
Kloeckener-Gruissem, B., Barthelmes, D., Labs, S., Schindler, C., Kurz-Levin, M., Michels, S., Fleischhauer, J., Berger, W., Sutter, F., & Menghini, M. (2011) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.10-6080 · Cited by 120 · cited 1×
“Patients homozygous for the CFH Y402H risk allele (CC genotype) were reported to have worse visual outcomes than CT or TT genotypes after ranibizumab or bevacizumab treatment in some studies.(13,18,36) In contrast, other studies reported no significant association between the CFH Y402H genotype and visual acuity chang…”
Apolipoprotein (APOE) gene is associated with progression of age-related macular degeneration (AMD)
Baird, P. N., Richardson, A. J., Robman, L. D., Dimitrov, P. N., Tikellis, G., McCarty, C. A., & Guymer, R. H. (2006) · Human Mutation · doi:10.1002/humu.20288 · Cited by 105
McKibbin, M., Ali, M., Bansal, S., Baxter, P. D., West, K., Williams, G., Cassidy, F., & Inglehearn, C. F. (2012) · British Journal of Ophthalmology · doi:10.1136/bjo.2010.193680 · Cited by 100
Orlin, A., Hadley, D., Chang, W., Ho, A. C., Brown, G., Kaiser, R. S., Regillo, C. D., Godshalk, A. N., Lier, A., Kaderli, B., et al. (2012) · Retina · doi:10.1097/iae.0b013e31822a2c7c · Cited by 60
Feng, X., Xiao, J., Longville, B., Tan, A. X. J., Wu, X. N., Cooper, M. N., McAllister, I. L., Isaacs, T., Palmer, L. J., & Constable, I. J. (2009) · Ophthalmology · doi:10.1016/j.ophtha.2009.03.011 · Cited by 54 · cited 1×
“As for CFH Y402H, Brantley et al(35) reported a worse visual outcome in PDT-treated patients with CFH Y402H TT genotype than other genotypes, whereas other studies reported that the proportion of PDT responder was comparable among the genotypes.(12) For VEGF gene, Immonen et al(31) reported that two SNPs (rs699947 and…”
Immonen, I., Seitsonen, S., Tommila, P., Kangas-Kontio, T., Kakko, S., Savolainen, E.-R., Savolainen, M. J., & Liinamaa, M. J. (2010) · Ophthalmology · doi:10.1016/j.ophtha.2009.06.037 · Cited by 45
Cited by
A paradigm shift in imaging biomarkers in neovascular age-related macular degeneration
Schmidt-Erfurth, U., & Waldstein, S. M. (2016) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2015.07.007 · Cited by 390
Wu, M., Xiong, H., Xu, Y., Xiong, X., Zou, H., Zheng, M., Wang, X., & Zhou, X. (2017) · British Journal of Ophthalmology · doi:10.1136/bjophthalmol-2016-309418 · Cited by 36
Chen, G., Tzekov, R., Li, W., Jiang, F., Mao, S., & Tong, Y. (2015) · Scientific Reports · doi:10.1038/srep14517 · Cited by 31
Wang, Z., Zou, M., Chen, A., Liu, Z., Young, C. A., Wang, S., Zheng, D., & Jin, G. (2022) · Acta Ophthalmologica · doi:10.1111/aos.14970 · Cited by 22
Zhang, J., Liu, Z., Hu, S., & Qi, J. (2021) · Ophthalmic Research · doi:10.1159/000508738 · Cited by 15
“Finally, a total of 21 preferred studies regarding the association between ARMS2 gene and the anti-VEGF treatment response in advanced AMD were generally included in the current meta-analysis [18-38].”
Background
Metadata
- Authors
- Park, U. C., Shin, J. Y., Kim, S. J., Shin, E. S., Lee, J. E., McCarthy, L. C., Newcombe, P. J., Xu, C.-F., Chung, H., & Yu, H. G.
- Venue
- Retina
- Published
- 2014-02
- Volume
- 34
- Issue
- 2
- Pages
- 288-297
- ISSN
- 0275-004X (ISSN-L)
- OpenAlex
- W1984218356
- Cited by
- 35
- References
- 14
- FWCI
- 3.61
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.